产品
编 号：F617223
分子式：C21H25NO6
分子量：387.43
分子式：C21H25NO6
分子量：387.43
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 116409-29-1
产品详情
生物活性：
NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5.
体内研究：
NSC-370284 (2.5?mg/kg；腹腔注射，每天一次，持续 10 天) 改善了 MLL-AF9 急性髓系白血病 (AML) 小鼠模型外周血 (PB)、骨髓 (BM)、脾和肝组织的病理形态学。Animal Model:C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice.
Dosage:2.5?mg/kg.
Administration:Intraperitoneal injection, once daily, for 10 days.
Result:Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice.
体外研究：
NSC-370284 (0-500 nM；24 h 或 48 h) 通过靶向 STAT3/5 抑制 MONOMAC-6、THP-1、KOCL-48 和 KASUMI-1 急性髓系白血病 (AML) 细胞活力。NSC-370284 显著下调 TET1 转录水平。
NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5.
体内研究：
NSC-370284 (2.5?mg/kg；腹腔注射，每天一次，持续 10 天) 改善了 MLL-AF9 急性髓系白血病 (AML) 小鼠模型外周血 (PB)、骨髓 (BM)、脾和肝组织的病理形态学。Animal Model:C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice.
Dosage:2.5?mg/kg.
Administration:Intraperitoneal injection, once daily, for 10 days.
Result:Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice.
体外研究：
NSC-370284 (0-500 nM；24 h 或 48 h) 通过靶向 STAT3/5 抑制 MONOMAC-6、THP-1、KOCL-48 和 KASUMI-1 急性髓系白血病 (AML) 细胞活力。NSC-370284 显著下调 TET1 转录水平。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备